Field Therapy in the Treatment of Actinic Keratosis

Actinic keratosis (AK) treatment represents a large and ever-increasing burden to our health care system, with the direct cost of therapy estimated to be more than $1 billion annually. There has been a great investment in developing an ideal treatment of AK that is effective, convenient, and minimizes adverse effects. Although targeting individual lesions with cryotherapy remains the mainstay of many practices, field therapy treats subclinical lesions as well as clinically apparent AK.